Express Scripts drops coverage of Valeant diabetes drug Glumetza
NEW YORK (Reuters) - Express Scripts Holding Co, the U.S. No. 1 pharmacy benefits manager, said on Friday it would stop covering Glumetza, a diabetes drug made by Valeant Pharmaceuticals International Inc, after a generic competitor enters the market on Feb. 1.
Aucun commentaire:
Enregistrer un commentaire